Cargando…
Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy
Interleukin-2 (IL-2) associated cholecystopathy is a rare manifestation of IL-2 drug toxicity in the setting of cancer immunotherapy. While the imaging data and clinical presentation can easily mimic acute cholecystitis, the correct diagnosis can be made with the particular clinical history, thus av...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641551/ https://www.ncbi.nlm.nih.gov/pubmed/26576289 http://dx.doi.org/10.1177/2058460115579458 |
_version_ | 1782400214979575808 |
---|---|
author | Kuppler, Kevin Jeong, Daniel Choi, Jung W |
author_facet | Kuppler, Kevin Jeong, Daniel Choi, Jung W |
author_sort | Kuppler, Kevin |
collection | PubMed |
description | Interleukin-2 (IL-2) associated cholecystopathy is a rare manifestation of IL-2 drug toxicity in the setting of cancer immunotherapy. While the imaging data and clinical presentation can easily mimic acute cholecystitis, the correct diagnosis can be made with the particular clinical history, thus avoiding inappropriate surgical management. As more cancer immunotherapies become standard oncologic treatments, specific immunotherapy-associated side effects are also expected to be encountered more frequently in the future and should be recognized as such. We present a case of IL-2-associated cholecystopathy in the setting of renal cell carcinoma immunotherapy. |
format | Online Article Text |
id | pubmed-4641551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-46415512015-11-16 Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy Kuppler, Kevin Jeong, Daniel Choi, Jung W Acta Radiol Open Case Report Interleukin-2 (IL-2) associated cholecystopathy is a rare manifestation of IL-2 drug toxicity in the setting of cancer immunotherapy. While the imaging data and clinical presentation can easily mimic acute cholecystitis, the correct diagnosis can be made with the particular clinical history, thus avoiding inappropriate surgical management. As more cancer immunotherapies become standard oncologic treatments, specific immunotherapy-associated side effects are also expected to be encountered more frequently in the future and should be recognized as such. We present a case of IL-2-associated cholecystopathy in the setting of renal cell carcinoma immunotherapy. SAGE Publications 2015-09-25 /pmc/articles/PMC4641551/ /pubmed/26576289 http://dx.doi.org/10.1177/2058460115579458 Text en © The Foundation Acta Radiologica 2015 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Kuppler, Kevin Jeong, Daniel Choi, Jung W Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title | Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title_full | Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title_fullStr | Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title_full_unstemmed | Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title_short | Non-infectious cholecystopathy secondary to high-dose IL-2 cancer immunotherapy |
title_sort | non-infectious cholecystopathy secondary to high-dose il-2 cancer immunotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641551/ https://www.ncbi.nlm.nih.gov/pubmed/26576289 http://dx.doi.org/10.1177/2058460115579458 |
work_keys_str_mv | AT kupplerkevin noninfectiouscholecystopathysecondarytohighdoseil2cancerimmunotherapy AT jeongdaniel noninfectiouscholecystopathysecondarytohighdoseil2cancerimmunotherapy AT choijungw noninfectiouscholecystopathysecondarytohighdoseil2cancerimmunotherapy |